Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vorapaxar. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R known ✓ | P25116 | 20/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vorapaxar SCHEMBL14203668 | 1.00 | F2R (1.00) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| Vorapaxar SCHEMBL14203679 | 1.00 | F2R (1.00) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| Vorapaxar SCHEMBL14203650 | 1.00 | F2R (1.00) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| Vorapaxar SCHEMBL14203585 | 1.00 | F2R (1.00) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| Vorapaxar SCHEMBL14203487 | 1.00 | F2R (1.00) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| Vorapaxar SCHEMBL14203623 | 1.00 | F2R (1.00) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| Vorapaxar SCHEMBL24988797 | 1.00 | F2R (1.00) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| Vorapaxar SCHEMBL14203526 | 1.00 | F2R (1.00) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| Vorapaxar SCHEMBL14203523 | 1.00 | F2R (1.00) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| Vorapaxar SCHEMBL22122697 | 1.00 | F2R (1.00) | F2RABCB11ADORA3CHRM1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | ORPHELION AB (SE) | 2026-05-07 | — | — | US | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| US-20260053804-A1 | Compositions and Methods for the Restoration of Ciliary Function | UNIV YALE (US) | 2026-02-26 | — | — | US | claimed |
| EP-4698160-A1 | TIMESCALE-GUIDED MICROFLUIDIC SYNTHESIS OF POLYPHENOL-IRON III NETWORK NANOCAPSULES OF HYDROPHOBIC DRUGS | Purdue Research Foundation (US) | 2026-02-25 | — | — | EP | claimed |
| US-12521258-B2 | Anticoagulant compounds and methods and devices for their use | ELIXIR MEDICAL CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20250388639-A1 | Therapeutic applications based on the inhibition of G Protein-Coupled Receptor 182 (GPR182) | MAX PLANCK GESELLSCHAFT (DE) | 2025-12-25 | — | — | US | claimed |
| US-20250381156-A1 | TREATMENT OR PREVENTION OF CARDIOVASCULAR EVENTS VIA THE ADMINISTRATION OF A COLCHICINE DERIVATIVE | MURRAY AND POOLE ENTPR LTD (GI) | 2025-12-18 | — | — | US | claimed |
| EP-4644426-A1 | ANTIBODY AGAINST COAGULATION FACTOR XI AND/OR ACTIVATED FORM FACTOR XIA THEREOF, AND USE THEREOF | Gan & Lee Pharmaceuticals Co., Ltd. (CN) | 2025-11-05 | — | — | EP | claimed |
| US-12419914-B2 | Thrombosomes as an antiplatelet agent reversal agent | CELLPHIRE, INC. (US) | 2025-09-23 | — | — | US | claimed |
| EP-4583872-A1 | MGLUR5 RECEPTOR ANTAGONISTS FOR USE IN PREVENTION AND/OR TREATMENT OF BONE MARROW LESIONS (BML) AND/OR OSTEOPOROSIS, CARTILAGE LOSS, OSTEOSCLEROSIS, OSTEITIS IN A MAMMAL | ORPHELION AB (SE) | 2025-07-16 | — | — | EP | claimed |
| US-11344506-B2 | Rapidly disintegrating oral dissolvable film | CUREX PHARMACEUTICAL MEXICO S.A.P.I. DE C.V. (MX) | 2022-05-31 | — | — | US | claimed |
| US-20220162338-A1 | ANTI-FXI/FXIA ANTIBODY AND USE THEREOF | KLUS PHARMA INC. | 2022-05-26 | — | — | US | claimed |
| US-11325937-B2 | Glycoside compound and preparation method therefor, composition, application, and intermediate | SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) | 2022-05-10 | — | — | US | claimed |
| CN-114432451-A | Immunological mechanism of gastrointestinal tract disease and therapeutic medicine | 广州市妇女儿童医疗中心 | 2022-05-06 | — | — | CN | claimed |
| CN-114450066-A | Thrombosomes as antiplatelet agent reversal agents | 塞尔菲乐有限公司 | 2022-05-06 | — | — | CN | claimed |
| CN-111658659-B | Therapeutic agent for use in prevention and/or treatment of ischemic cerebrovascular disease | 上海和黄药业有限公司 | 2022-03-25 | — | — | CN | claimed |
| EP-3971571-A2 | COMPOSITIONS AND METHODS FOR ASSAYING PLATELET REACTIVITY AND TREATMENT SELECTION | The University of Vermont and State Agriculture College (US) | 2022-03-23 | — | — | EP | claimed |
| US-20220062247-A1 | USE OF A PAR-1 ANTAGONIST FOR THE TREATMENT OF A CHRONIC INFLAMMATORY INTESTINAL DISEASE | CVASTHERA (FR) | 2022-03-03 | — | — | US | claimed |
| WO-2022043490-A1 | ACTIVE AGENT COMBINATION FOR TREATMENT OF CANCER | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2022-03-03 | — | — | WO | claimed |
| EP-3957652-A1 | ANTI-FXI/FXIA ANTIBODY AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069593-A1 | METHODS FOR TREATING CANCER | KRAS, NRAS, HRAS | F2R 2401/4885ABCB11 2654/4885ADORA3 2568/4885 |
| US-20250388639-A1 | Therapeutic applications based on the inhibition of G Protein-Coupled Receptor 182 (GPR182) | GPR132, GPR142, FAM162A | F2R 1548/4885ABCB11 4489/4885ADORA3 1190/4885 |
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | GRM5, OPRL1, GRM1 | F2R 1035/4885ABCB11 640/4885ADORA3 188/4885 |
| US-11325937-B2 | Glycoside compound and preparation method therefor, composition, application, and intermediate | VEGFA, FLT4, FLT1 | F2R 1501/4885ABCB11 4227/4885ADORA3 520/4885 |
| US-20250381156-A1 | TREATMENT OR PREVENTION OF CARDIOVASCULAR EVENTS VIA THE ADMINISTRATION OF A COLCHICINE DERIVATIVE | PCSK9, HMGCR, FABP3 | F2R 3651/4885ABCB11 399/4885ADORA3 3566/4885 |
| US-20260053804-A1 | Compositions and Methods for the Restoration of Ciliary Function | MTCL3, DYNLL2, CEP170 | F2R 3331/4885ABCB11 1723/4885ADORA3 3808/4885 |
| US-20220062247-A1 | USE OF A PAR-1 ANTAGONIST FOR THE TREATMENT OF A CHRONIC INFLAMMATORY INTESTINAL DISEASE | F2R, F2RL1, F2RL3 | F2R 1/4885ABCB11 2167/4885ADORA3 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.